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Abstract
Background/Aim: Hyperhomocysteinemia due to Methylenetetrahydrofolate Reductase (MTHFR) gene, in particular
the C677T (Ala222Val) polymorphism were recently associated to steatosis and fibrosis. We analyzed the frequency
of MTHFR gene in a cross-sectional study of patients affected by Chronic Hepatitis C (CHC) from Northeast of Brazil.
Method: One hundred seven-four untreated patients with CHC were genotyped for the C677T MTHFR. Genomic
DNA was extracted from peripheral blood cells and the C677T MTHFR polymorphism was identified by PCR-RFLP.
The homocysteine (Hcy) levels were determined by chemiluminescence method. All patients were negative for
markers of Wilson’s disease, hemochromatosis and autoimmune diseases and have current and past daily alcohol
intake less than 100 g/week.
Results: Among subjects infected with CHC genotype non-1 the frequency of MTHFR genotypes TT was 9.8%
versus 4.4% genotype 1 (p = 0.01). Nevertheless, association was found between the MTHFR genotype TT × CT/CC
polymorphism and the degree of steatosis and fibrosis in both hepatitis C genotype (p < 0.05). A significant
difference was found on plasma Hcy levels in patients with steatosis regardless of HCV genotype (p = 0.03).
Conclusion: Our results indicate that plasma Hcy levels is highly prevalent in subjects with chronic hepatits C with
steatosis regardless of HCV genotype and vitamin deficiency. The presence of genotype TT of MTHFR C677T
polymorphism was more common in CHC genotype non-1 infected patient regardless of histopathological
classification and genotype TT+CT frequencies were significant in the presence of fibrosis grade 1+2 and of
steatosis in CHC infected patients from the northeast of Brazil regardless of HCV genotype. The genetic
susceptibility of MTHFR C677T polymorphism should be confirmed in a large population.
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Introduction
Homocysteine (Hcy) belongs to a group of molecules
known as cellular thiols. It is considered a “bad thiol”
because its association with a variety of health condi-
tions including cardiovascular disease, [1] end-stage
renal disease, [2] neural tube defects, [3] and cognitive
dysfunctions including Alzheimer disease [4]. Recently,
homocysteine has also been implicated in the pathogen-
esis of alcoholic liver injury [5].
One of the most common mutations, or polymorph-
isms, that are associated with a mild increase in plasma
homocysteine (hyperhomocysteinemia) is the 677C®T
substitution (an alanine to valine change) in the enzyme
methylenetetrahydrofolate reductase (MTHFR). The
MTHFR is an enzyme of the folate metabolism that
reduces 5,10- metilenetetraidrofolate (5,10-mTHFR) to
5-metiltetraidrofolate (5-mTHF), an important co-factor
to homocysteine (Hcy) methylation. Mutations in
MTHFR gene like C677T result in amino acids
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[6,7]. As a consequence of the MTHFR dysfunctions, an
increased Hcy level in plasma has been expected which,
in turn, produces a cytotoxic effect [8].
The frequency of this variant in the homozygous state
varies from 0% to1% in African Americans to 25% in
Hispanic Americans, ranging for most populations
(Canada and United States, Europe, Asia, and Australia)
between 10% to 15% [9]. Recently, it has been shown
that hyperomocysteinaemia, in relationship with the
methylenetetrahydrofolate reductase, MTHFR C677T
polymorphism, favours steatosis and fibrosis in HCV
infected immune competent individuals through an
alteration of lipid metabolism [10].
Human hepatitis C virus (HCV) infects about 2-3% of
the world population. HCV infection leads to chronic
hepatitis in up to 60-80% of infected individuals [11]
and is associated with liver steatosis, fibrosis, cirrhosis,
and hepatocellular carcinoma (HCC) [12].
Most studies have reported approximately 50% preva-
lence of steatosis among patients undergoing a liver
biopsy because of HCV [13,14]. In patients with HCV
infection there is a ‘’metabolic fat’’ (especially in patients
with HCV genotype 1) and a ‘’viral fat’’ (especially in
patients with genotype 3).
Genotype 3 is the only subtype that has been shown
to correlate with a higher grade of steatosis independent
of other host-related factors, such as the presence of
nonalcoholic fatty liver disease (NAFLD) [15]. The
severity of steatosis in these patients is directly related
to the burden of the HCV RNA viral load, and resolu-
tion of steatosis is often observed with the loss of vire-
mia after antiviral treatment [16,17]. It has been
postulated that HCV genotype 3 can cause steatosis also
by interfering with triglyceride secretion. Otherwise, in
genotype 1 infection is attributable to metabolic pertur-
bations caused by activation of proinflammatory
mechanisms and underlying obesity and insulin
resistance.
T h ea i mo ft h ep r e s e n ts t u d yw a st oi n v e s t i g a t e
whether MTHFR C677T polymorphism might play a
role in progression of fibrosis and steatosis in hepatitis
C patients from Northeast of Brazil and correlate with




We studied one hundred seven-four naive patients with
chronic hepatitis C infection (CHC) from the Northeast
of Brazil (91 male, 83 female). All patients enrolled had
increased aminotransferase levels for at least six months
and tested positive for anti-HCV antibodies (third-gen-
eration enzyme immunoassay) and HCV-RNA (RT-PCR,
Roche Cobas Amplicor 2.0, Roche Diagnostics, Basel,
Switzerland).
The HCV genotype, determined by LiPA assay (Inno-
lipa HCV II; Immunogenetics, Ghent, Belgium). All
patients were enrolled at the Liver Institute of Pernam-
buco in Brazil from February 2007 to October 2009.
This cross-sectional study was conducted according
with the Helsinki declaration of 1975. Specific informed
consent was obtained for the study and the protocol
was approved by the Internal Review Board of the Uni-
versity of Pernambuco- Brazil. The investigations per-
formed to exclude other causes of liver disease included
a hepatobiliary system ultrasound, viral serology, autoan-
tibody titers, serum iron, ferritin and transferrin satura-
tion, ceruloplasmin and copper levels, and alpha1-
antitrypsin. Patients who had a > 100 g/week alcohol
intake determined by a detailed personal history, ques-
tioning of family members, and an investigation of pre-
vious medical records, were excluded. Also it was
excluded treatment with immunosuppressive drugs or
drugs causing steatosis (corticosteroids, antiepileptic
agents, tamoxifen and amiodarone).
The diagnosis of diabetes type II, hypertension, and
dyslipidemia were based on the criteria of the American
Diabetes Association (Alexandria, VA, USA); fasting glu-
cose ≥ 100 mg/dL; triglyceride (Tg) ≥ 150 mg/dL; high
density lipoprotein (HDL) < 40 mg/dL in men or < 50
mg/dL in women; and ≥ 130 mmHg systolic or ≥ 85
mmHg diastolic) [18]. The folic acid and B12 vitamin
reference were 3.1-17.5 ng/mL and 197-866 pg/mL
respectively.
Normative reference Hcy levels were considered to be
12 or less (μmol/L) in males and 10 or less in females
[10]. The homocysteine cut-off level in this study was 9
μmol/L determined by ROC curve.
Study Design and Laboratory assays
The MTHFR polymorphism was analyzed in all 174
patients, however only in 138 of these patients the
serum samples were collected at the time of liver biopsy.
Thus, we used 138 serum samples to determine total
cholesterol, low-density lipoprotein (LDL), high-density
lipoprotein (HDL), triglycerides (Tg), alanine amino-
transferase (ALT), aspartate aminotransferase (AST),
gamma-glutamyl transferase (gGT), alkaline phosphatase
(AP), fasting glucose, fasting insulin, and insulin resis-
tance (homeostasis model assessment-insulin resistance
[HOMA-IR]: fasting insulin (U/mL) fasting glucose
(mmol/L)/22.5) [19]. For insulin resistance the cut-off
value was considered to be ≥ 2.5. Blood samples were
centrifuged within 60 min to separate plasma, serum
and leukocyte cells and storaged at-80 °C.
The homocysteine levels were determined by chemilu-
minescence method [20]; Fasting Glucose, total
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gGT and fasting insulin were performed by standard
methods using automated techniques (Cobas, Roche).
The LDL cholesterol was determined by Friedwald
equation [21].
The C677T polymorphism was determined by a poly-
merase chain reaction restriction fragment length poly-
morphism (PCR-RFLP) assay. The C®T transition
creates a restriction site for the enzyme Hinf Ia n dt h e
digested product was isolated electrophoretically in 2%
agarose gel and the fragments were visualized in ultra-
violet light (UV) after being stained with ethidium bro-
mide. Wild type (CC) shows a single fragment of 198
bp; heterozygote (CT) shows fragments of 198, 175 and
23 bp; and mutant homozygote (TT) shows two frag-
ments with 175 and 23 bp [22].
Histological analysis
The liver tissue was fixed in 4% formaldehyde and pro-
cessed for hematoxylin-eosin and Masson trichrome
stains for histological analysis. Histological analyses were
evaluated by only one pathologist who was unaware of
the HCV genotype and of the patient’s clinical charac-
teristics. Stages of fibrosis and grades of inflammation
were scored according to METAVIR, that it consists of
F0 (no fibrosis), F1 (portal fibrosis without septa), F2
(portal fibrosis with few septa), F3 (numerous septa
without cirrhosis), F4 (cirrhosis). Steatosis was graded 0-
3 based on percentages of hepatocytes harbouring lipid
droplets in the biopsy (0 reflecting none; 1 equalling 40-
33%; 2 referring to 33-66%; and 3 representing > 66%
steatotic hepatocytes).
Statistical analysis
Data analysis was performed with SPSS 15.0 software.
Distribution normality of the groups considered was
preliminary evaluated by Kolmogorov-Sminorv test. Dif-
ferences between groups were analyzed by analysis of
variance (ANOVA) when variables were normally dis-
tributed. Chisquare test or Fisher’s exact test were used
to compare categorical variables. Logistic regression ana-
lysis was used to identify independent predictors for
MTHFR polymorphism, gender, triglyceride, fibrosis and
steatosis. The proportion of MTHFR alleles were distrib-
uted in patients in accordance with the Hardy-Weinberg
equilibrium. Results were considered significant when
the p value was less than 0.05.
Results
Clinical and biochemical analysis
In the present study 174 patients with CHC were
included. There were 52.3% (91/174) males and 47.7%
(83/174) females. The biochemical characteristics
according genotype and histological classification were
only analyzed in 138 patients with CHC and the patients
were stratified according to viral genotype 1 (n = 93)
and non-1 (n = 45).
The biochemical characteristics according to the geno-
type classification demonstrated Hcy levels and concen-
trations of total cholesterol differ significantly between
patients with genotype 1 and genotype non-1 (9.96 ver-
sus 9.39 μmol/L and 158.01 versus 138.58 mg/dL,
respectively, p = 0.01) (Table 1). The Hcy level differs
significantly between no steatosis and steatosis (9.0 ver-
sus 10.3 μmol/L respectively, p = 0.03) (Table 2).
Although neither folate and vitamin B12 nor triglycer-
ides, total cholesterol, HDL, LDL, HOMA, glucose and
Hcy level differ between genotypes frequencies of the
677C/T (MTHFR) polymorphism (p > 0.05) (Table 3).
MTHFR 677C/T polymorphism
The MTHFR p o l y m o r p h i s mw a sa n a l y z e df r o mp e r i p h -
eral blood of 174 patients. The genotype TT was more
frequent in HCV non-1 genotype than genotype 1 (9.8%
versus 4.4% respectively, p = 0.01) (Table 4). Associated
with this no relation was observed in the genotype fre-
quencies of the 677C/T (MTHFR) polymorphism
according to HCV genotype and histopathological classi-
fication (p > 0.05) (Table 5). Hence, a significant differ-
ence was observed in the genotype TT+CT frequencies
according to histological grades of fibrosis (1+2 [n =
116] versus 3+4 [n = 58]) (p = 0.001) and of steatosis
Table 1 Clinical and biochemical characteristics of CHC






Age 54.06 51.59 0.14
Fasting Glucose 92.58 100.13 0.80
Homocysteine* (μmol/L) 9.96 9.39 0.01*
HOMA 2.72 3.35 0.74
AST (UI) 68.69 73.24 0.97
ALT(UI) 84.02 91.56 0.58
gGT(UI) 86.06 84.31 0.93
AP(UI) 83.03 72.67 0.26
Total Cholesterol*(mg/dL) 158.01 138.58 0.01*
HDL (mg/dL) 49.05 46.73 0.29
LDL(mg/dL) 88.00 74.44 0.10
Triglycerides (mg/dL) 105.89 91.69 0.05*
*p significative
References values:
AST: Male- 10-34 UI, Female- 10-36 UI; ALT: Male- 10-44 UI, Female-10-36 UI;
gGT: Male- 11-50 UI, Female-7-32 UI; AP: Male- 45-122 UI, Female-32-104 UI;
Cholesterol: < 200
mg/dl; Triglycerides: < 150 mg/dl; HDL: > 40 mg/dl; Glucose: < 100 mg/dl;
HOMA homeostasis
model assessment for insulin resistence (value < 2.5), Homocysteine < 9.0
μmol/L.
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0.04) regardless of HCV genotype (Table 6).
In multi regression analysis no relation were observed
among MTHFR polymorphism, Hcy level, HCV geno-
type and lipid profile as a independent variables for stea-
tosis and fibrosis (Table 7 and 8).
Discussion
The heterogeneity of Brazilian population regarding
racial definition mixed with social economic factors may
represent a confounding factor herein. The absence of
information on the reported genetic risk factors in the
Northeast of Brazil population, which is considered to
be genetically very heterogeneous, led us to design the
present study. In our data we reported that the genotype
TT was more frequent in the HCV genotype non-1
without association with histological grades of fibrosis
and of steatosis. We also observed significant difference
in the genotype TT+CT frequencies according to histo-
logical grades of fibrosis and steatosis regardless of HCV
genotype.
Several biological and clinical implications have been
suggested to occur in relationship with the MTHFR
677C/T polymorphism. The MTHFR polymorphisms
were found to be associated with increased cardiovascu-
lar risk in several populations including Lebanese, Japa-
nese and French Canadians [23-25]. Toniutto et al., also
found a relation between MTHFR 677C/T polymorph-
ism and liver fibrosis in patients who underwent liver
transplantation with recurrent hepatitis C and also spec-
ulates that the MTHFR polymorphism could play a
direct profibrogenic effect, modulating the action of pro-
teins involved in collagen degradation [26].
Otherwise Borgia et al. did not find association with
polymorphisms of MTHFR in the outcome of pegylated-
IFNa plus ribavirin treatment in patients with chronic
hepatitis C, only the homocysteine levels [27]. Silva et
al., only confirms the association between increased
plasma homocysteine concentration in Alzheimer’sd i s -
e a s ea n ds u g g e s t st h a tC 6 7 7 TMTHFR polymorphisms
not contributed to genetic susceptibility for Alzheimer’s
disease in elderly individuals in the Northeast of Brazil
[28].
However, another study conducted in Northeast of
Brazil, Couto et al., screened 843 neonates for MTHFR
C677T polymorphism. The T677 allele frequency and
Table 2 Plasma levels of Homocysteine in CHC virus





Fibrosis 1+2 (n = 105) 9.7 ± 4.7
Fibrosis 3+4 (n = 40) 10.4 ± 2.9 0.30
No Steatosis (n = 46) 9.0 ± 2.8
Steatosis (n = 99) 10.3 ± 4.8 0.03*
Genotype 1 (n = 96) 10.1 ± 2.9
Genotype Non -1 (n = 49) 9.5 ± 6.1 0.55
References values: Homocysteine < 9.0 μmol/L *p significative
Table 3 Biochemical characteristics of the 677C/T
(MTHFR) polymorphisms in CHC
Variables CT+TT
Media ± SD (n = 65)
CC
Media ± SD (n = 73)
p
Total Cholesterol 147.3 ± 33.7 155.6 ± 43.8 0.21
HDL 47.5 ± 14.4 49.0 ± 13.9 0.55
LDL 79.7 ± 30.4 87.0 ± 39.8 0.23
Triglyceride 103.4 ± 40.6 99.4 ± 45.9 0.59
Fasting Glucose 97.4 ± 37.5 93.0 ± 18.1 0.39
Folate 12.9 ± 2.8 12.4 ± 2.8 0.33
Vit.B12 766.7 ± 361.8 652.8 ± 278.3 0.09
HOMA 3.2 ± 2.9 2.7 ± 1.8 0.21
Homocysteine 10.2 ± 5.4 9.5 ± 2.8 0.31
References values
Triglyceride < 150 mg/dL, Total Cholesterol < 200 mg/dL, LDL-c < 130 mg/dL,
HDL-c > 40 mg/dL, HOMA: < 2.5.
Glucose: < 100 mg/dl, Folate 3.1-17.5 ng/mL, Vit. B12 197-866 pg/mL,
Homocysteine < 9.0 μmol/L.
Table 4 Genotype frequencies of the 677C/T (MTHFR)
polymorphisms in CHC patients according genotype and
histopathological classification
Genotype frequencies (%)
MTHFR TT CT CC p
Steatosis (n = 104) 5.7 40.4 53.8 0.80
No Steatosis (n = 70) 7.1 41.4 51.4
Fibrosis 1+2 (n = 116) 5.1 37.9 56.9 0.21
Fibrosis 3+4 (n = 58) 8.6 46.5 44.8
Genotype 1 (n = 113) 4.4 35.4 60.1 0.01*
Genotype Non-1 (n = 61) 9.8 50.8 39.3
*p significative
Table 5 Genotype frequencies of the 677C/T (MTHFR)
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other studies of African-descent populations. The T
allele frequency was 0.23 and the C/T and T/T geno-
types prevalence were 36.2 and 5.3 percent, respectively
[29].
The present study provides evidence that a genetic
background, such as the MTHFR polymorphism through
hyperhomocysteinemia induced derangement of lipid
metabolism, may contribute to the development of
higher degrees of steatosis, which in turn accelerates the
progression of liver fibrosis in chronic HCV infection.
Potential mechanisms of this effect may include the
increased sensitivity of steatotic livers to oxidative stress,
cytokine-mediated injury, and steatosis-related hepatic
insulin resistance [30].
Other important finding of our study was the higher
Hcy level in patients with steatosis, although the
MTHFR polymorphism was not identified as a risk fac-
tor for steatosis in the whole population (HCV geno-
types 1+ non-1) in the multi regression analysis. It
should be understood because the high plasma levels of
Hcy have been reported to negatively influence normal
cell function in many different tissues, such as vascular
endothelium and smooth muscle cells and the liver.
These effects, in turn, may explain the association of
hyperhomocysteinaemia with vascular disease (thrombo-
sis of arterial and venous districts and atherosclerosis)
[31-36] and more recently, have been advocated for a
possible role in pathogenesis and evolution of chronic
liver disease [36,37].
H c yi sat o x i cn o n - p r o t e i ns u l f u rc o n t a i n i n ga m i n o
acids in humans. It is formed exclusively upon demethy-
lation of the essential amino acid- methionine. The Hcy
metabolism occurs through the junction of the remethy-
lation and transsulfuration pathways. These pathways
are strongly influenced by enzymes polymorphisms.
MTHFR enzyme has fundamental importance in plas-
matic Hcy regulation [38,39].
Hcy decreases the expression of a wide range of anti-
oxidant enzymes [40-42] and impairs endothelial nitric
oxide (NO) bioavailability by inhibiting glutathione per-
oxidase activity raise the possibility that Hcy sensitizes
cells to the cytotoxic effects of agents or conditions
known to generate reactive oxygen species (ROS).
Decreased NO bioavailability has also been shown in
vitro to increase the expression of monocyte chemoat-
tractant protein 1 (MCP-1) which may enhance intra-
vascular monocyte recruitment and lead to accelerated
lesion formation [43].
There is evidence that Hcy induced endoplasmic reti-
culum (ER) stress causes dysregulation of the endogen-
ous sterol response pathway, thereby leading to
increased hepatic biosynthesis and uptake of cholesterol
and triglycerides without impairing the hepatic export of
lipids [44]. Similar result was observed in Adinolfi et al.,
studies that investigated the role of these factors in the
development of HCV related steatosis and in the pro-
gression of chronic hepatitis C in 116 patients, 50% had
a body mass index (BMI) of 25 or higher; 58% were
infected with HCV genotype 1, and 65.5% showed stea-
tosis. According to multivariate analysis, steatosis was
independently associated with hyperhomocysteinemia
(OR = 7.1) [10].
We also observed lower concentrations of serum total
cholesterol in CHC patients genotype non-1. Similar
Table 6 Genotype frequencies of the 677C/T (MTHFR)





Fibrosis 1+2 (n = 116) 68.3
Fibrosis 3+4 (n = 58) 31.7 0.001*
No Steatosis (n = 70) 37.8
Steatosis (n = 104) 62.8 0.04*
*p significative
Table 7 Multi regression analysis in which MTHFR polymorphism, Homocysteine level, HCV genotype and lipid profile
as a independent variables for steatosis
Variables OR (CI 95%) p* OR adjusted p OR adjusted p
Gender: F/M 1.1 (0.6-2.0) 0.88 1.1(0.5-2.3) 0.90 1.1 (0.5-2.3) 0.87
HOMA ≥ 2.5 1.5 (0.7-3.2) 0.35 1.3 (0.6-2.9) 0.40 1.4 (0.7-3.1) 0.35
LDL cholesterol ≥ 130 0.5 (0.2-1.6) 0.35 0.6 (0.2-1.9) 0.35 - (**) -
HDL cholesterol ≤ 40 1.1 (0.5-2.4) 0.84 0.9 (0.4-2.1) 0.82 1.0 (0.4-2.2) 0.93
Total Cholesterol ≥ 200 0.8 (0.2-2.9) 0.75 - (**) - 0.9 (0.2-3.6) 0.96
Triglyceride ≥ 150 0.6 (0.2-1.8) 0.38 0.6 (0.2-1.9) 0.40 0.6 (0.2-1.9) 0.37
TT+CT (MTHFR) 0.8 (0.4-1.5) 0.64 1.0 (0.5-2.1) 0.94 1.0 (0.5-2.1) 0.95
Homocysteine ≥ 9 1.6 (0.8-3.3) 0.18 1.6 (0.7-3.3) 0.24 1.6 (0.7-3.3) 0.25
*Fisher Test ** Collinearity
References values:
Triglyceride < 150 mg/dL, Total Cholesterol < 200 mg/dL, LDL-c < 130 mg/dL, HDL-c > 40 mg/dL, HOMA: < 2.5, Homocysteine < 9.0 μmol/L
CI: confidence interval
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strated that serum lipids play a role in hepatitis C virion
circulation and hepatocyte entry. In a cohort of 179
patients with CHC this author showed that patients
with HCV had lower concentrations of total cholesterol
than in the control group. These data support the
hypothesis that the lipo-viral particles use the LDL-C
receptors of hepatocytes as points of entry of the virus.
Once inside into hepatocyte, the replication dependents
of the lipid environment of the host [45-47].
In summary, our study had important implications.
According to our data, Hcy levels were highly prevalent
in subjects with chronic hepatits C with steatosis regard-
less of HCV genotype and vitamin deficiency. The pre-
sence of genotype TT of MTHFR C677T polymorphism
was more common in CHC genotype non-1 infected
patient regardless of histopathological classification and
genotype TT+CT frequencies were significant in the
presence of fibrosis grade 1+2 and of steatosis in CHC
infected patients from the northeast of Brazil. The
genetic susceptibility of MTHFR C677T polymorphism
should be confirmed in a large population.
Conclusion
The MTHFR C677T polymorphism frequencies were
significant in the presence of fibrosis and of steatosis in
CHC infected patients from the northeast of Brazil
regardless of homocysteine levels and HCV genotype.
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